Precigen Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Precigen şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.02%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.02%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: I5X şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: I5X şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Precigen Piyasaya Karşı Temettü Getirisi

I5X temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (I5X)	n/a
Pazarın Alt %25'i (DE)	1.7%
Pazarın En İyi %25'i (DE)	4.9%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (I5X) (3 yıla kadar)	n/a

Önemli Temettü: I5X şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, I5X şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: I5X şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: I5X herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Precigen Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.082 loss in 2Q 2023)

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New major risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

New major risk - Share price stability

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Precigen, Inc., Annual General Meeting, Jul 05, 2024

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.099 loss in 1Q 2023)

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

Full year 2023 earnings released: US$0.39 loss per share (vs US$0.40 loss in FY 2022)

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Forecast to breakeven in 2026

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.038 loss in 3Q 2022)

Independent Director recently bought €630k worth of stock

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.13 loss in 2Q 2022)

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

First quarter 2023 earnings released: US$0.099 loss per share (vs US$0.12 loss in 1Q 2022)

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Now 20% undervalued after recent price drop

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Third quarter 2022 earnings released: US$0.038 loss per share (vs US$0.15 loss in 3Q 2021)

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Chief Financial Officer recently bought €51k worth of stock

Independent Director recently sold €111k worth of stock

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.10 loss in 2Q 2021)

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

First quarter 2022 earnings released: US$0.096 loss per share (vs US$0.11 loss in 1Q 2021)

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Precigen, Inc. to Report Q1, 2022 Results on May 09, 2022

Precigen, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Precigen, Inc. Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Precigen, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Precigen, Inc Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

Insufficient new directors

Executive Chairman recently bought €3.2m worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

VP of Finance & Accounting and Principal Accounting Officer D. Osborne has left the company

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 1Q 2020)

Chief Financial Officer has left the company

Revenue misses expectations

Full year 2020 earnings released: US$0.62 loss per share (vs US$1.10 loss in FY 2019)

Precigen, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $112.5 million.

Precigen, Inc. Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis

New 90-day high: €8.85

Precigen, Inc. Provides Latest Clinical Developments At Virtual R&D Update Event

Zhang Investor Law Alerts Investors to December 4 Deadline in Securities Class Action Lawsuit Against Precigen, Inc

New 90-day high: €6.20

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries

Precigen, Inc Announces Clinical Implementation of Its UltraPorator System

Bernstein Liebhard Reminds Investors of the Deadline to File A Lead Plaintiff Motion in A Securities Class Action Lawsuit Against Precigen Inc

Precigen, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Pomerantz Law Firm Announces the Filing of Class Action Against Precigen, Inc

Precigen, Inc. Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials